OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+60.43%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$242M
AUM Growth
+$242M
(+9.1%)
Cap. Flow
-$10.2M
Cap. Flow
% of AUM
-4.21%
Top 10 Holdings %
Top 10 Hldgs %
67.89%
Holding
53
New
6
Increased
20
Reduced
10
Closed
11
Top Buys
| 1 |
Rhythm Pharmaceuticals
RYTM
|
$11M |
| 2 |
TELA Bio
TELA
|
$3.35M |
| 3 |
Larimar Therapeutics
LRMR
|
$2.33M |
| 4 |
Ocular Therapeutix
OCUL
|
$2.03M |
| 5 |
Edgewise Therapeutics
EWTX
|
$1.81M |
Top Sells
| 1 |
Kiniksa Pharmaceuticals
KNSA
|
$7.89M |
| 2 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$5.58M |
| 3 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$5.34M |
| 4 |
908 Devices
MASS
|
$3.43M |
| 5 |
Celldex Therapeutics
CLDX
|
$2.43M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Harrow
HROW
$1.44B
| $40.4M | 16.67% | 3,343,817 +11,085 | +0.3% | +$134K |
|
|
2
Ocular Therapeutix
OCUL
$2.12B
| $26.8M | 11.08% | 6,465,000 +490,200 | +8% | +$2.03M |
|
|
3
Rhythm Pharmaceuticals
RYTM
$6.85B
| $19.8M | 8.2% | 810,000 +448,000 | +124% | +$11M |
|
|
4
TELA Bio
TELA
$70.5M
| $17.4M | 7.17% | 2,036,551 +393,184 | +24% | +$3.35M |
|
5
Crinetics Pharmaceuticals
CRNX
$2.92B
| $13.2M | 5.45% | 671,300 | – | – |
|
6
Cytokinetics
CYTK
$4.23B
| $12.7M | 5.26% | 263,000 -39,500 | -13% | -$1.91M |
|
7
Keros Therapeutics
KROS
$618M
| $12.1M | 4.99% | 321,300 +45,300 | +16% | +$1.7M |
|
8
Protara Therapeutics
TARA
$120M
| $7.99M | 3.3% | 2,708,067 +23,900 | +0.9% | +$70.5K |
|
9
Codexis
CDXS
$246M
| $7M | 2.89% | 1,155,000 -133,450 | -10% | -$809K |
|
|
TCON
10
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $7M | 2.89% | 4,190,000 +64,678 | +2% | +$108K |
|
|
CUTR
11
DELISTED
Cutera, Inc.
CUTR
| $6.74M | 2.78% | 147,700 | – | – |
|
|
12
Edgewise Therapeutics
EWTX
$1.51B
| $6.25M | 2.58% | 635,000 +183,600 | +41% | +$1.81M |
|
13
Mersana Therapeutics
MRSN
$36.5M
| $6.09M | 2.51% | 900,300 -146,700 | -14% | -$992K |
|
|
14
Larimar Therapeutics
LRMR
$310M
| $5.32M | 2.2% | 1,661,784 +728,970 | +78% | +$2.33M |
|
15
Eton Pharmaceutcials
ETON
$464M
| $5.29M | 2.19% | 2,521,000 +58,500 | +2% | +$123K |
|
|
INBX
16
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $5.25M | 2.17% | 292,700 -297,300 | -50% | -$5.34M |
|
17
Merus
MRUS
$4.98B
| $5.07M | 2.09% | 253,200 -84,800 | -25% | -$1.7M |
|
18
Vaxcyte
PCVX
$4B
| $4.56M | 1.88% | 190,000 | – | – |
|
19
Xoma
XOMA
$392M
| $4.44M | 1.83% | 248,000 -15,050 | -6% | -$270K |
|
20
UroGen Pharma
URGN
$900M
| $3.31M | 1.37% | 397,500 +158,830 | +67% | +$1.32M |
|
21
Liquidia Corp
LQDA
$2.38B
| $3.07M | 1.27% | 563,500 +42,000 | +8% | +$228K |
|
22
4D Molecular Therapeutics
FDMT
$288M
| $2.82M | 1.16% | 350,700 +25,700 | +8% | +$207K |
|
23
Stereotaxis
STXS
$261M
| $2.8M | 1.16% | 1,556,800 -543,171 | -26% | -$978K |
|
24
Fortress Biotech
FBIO
$76.8M
| $2.58M | 1.07% | 2,999,000 -248,180 | -8% | -$213K |
|
25
ProQR Therapeutics
PRQR
$237M
| $2.32M | 0.96% | 3,115,000 +375,000 | +14% | +$279K |
|